INTRODUCTION
India is one of the largest and most populated countries in the world, with over a billion inhabitants. There are currently an estimated 2.4 million Indians living with HIV/AIDS [1] . Although HIV infection emerged as late as 1986 in India, later than it did in many other countries, the infection rates rose sharply throughout the 1990s. In 1987 the Government of India launched a National AIDS Control Programme (NACP) to co-ordinate national responses which covered surveillance, blood screening, and health education [2] . By the end of 1987, of the 52,907 people tested, 135 people were found to be HIV positive and 14 had AIDS.
It is now clear that although individual states and cities in India had separate epidemics, HIV had spread to the general population by the 1990s. Currently, the epidemic affects all sectors of Indian society, even those initially considered not at risk [4] .
TREATMENT FOR PEOPLE LIVING WITH HIV
Antiretroviral drugs (ARVs), which can significantly delay the progression from HIV to AIDS -have been available in developed countries since 1996 [5] . There are currently over 30 ARVs available globally [6] . These include largely NRTIs, NNRTIs, Protease inhibitors, the new Fusion inhibitors, Entry inhibitors-CCR5 co-receptor antagonists and HIV integrase strand transfer inhibitors -both single drugs and fixed dose combinations (FDCs) ( Table 1) . The major originator companies include: Abbott, Boehringer Ingelheim (BI), Bristol-Myers Squibb (BMS), Gilead, GlaxoSmithKline (GSK), Merck, Pfizer, Roche, and Tibotec The drugs available in India thus include both single drug and FDCs covering both the first line and second line ARVs [10] [11] [12] . The Government of India launched the free antiretroviral treatment (ART) programme in 2004, starting with eight tertiary-level government hospitals in the six highprevalence states of India [3] . All persons with HIV infection who are clinically eligible to receive ART are included in the Phase I of the programme. The subgroups of the people living with HIV/AIDS (PLHA) targeted on a priority basis include: (i) sero-positive mothers who have participated in the prevention of parent-to-child transmission (PPTCT) programme; (ii) sero-positive children below the age of 15 years; and (iii) people with AIDS who seek treatment in government hospitals [3] . The free ART programme envisages a comprehensive prevention, care and treatment programme, with i) standardized, simplified combination of ART regimens; ii) regular secure supply of good-quality ARV drugs; and iii) a robust monitoring and evaluation system eventually working towards universal access to care and treatment [3] .
Linkages and referrals to other programmes as the prevention of parent-to-child transmission (PPTCT), programme are also being strengthened to enable women and children living with HIV/AIDS have greater access to treatment. The Phase I programme is also establishing linkages with other related national programmes as the Revised National Tuberculosis Control Programme (RNTCP), Reproductive and Child Health (RCH) Programme and the massive National Rural Health Mission (NRHM) [3] .
ACCESS TO ARVs IN INDIA
Currently there are over 160 ART ARV centers in 31 States and Union Territories [6] with an estimated 140,000 patients are receiving ARVs free of cost at these centers [13] . Another 35,000 patients are receiving free ARVs at ART centers run by NGOs and other organizations [3] . The ART centres are being scaled up in a phased manner to provide free ARVs to 100,000 patients by the end of 2007 and 300,000 patients by 2011 in 250 centres across India under phase III of NACO [13] . ARV drugs including combination containing ingredients for adults are: i) Two drug combination tablets containing Stavudine and Lamivudine; ii) Two drugs combination tablets containing Zidovudine and Lamivudine; iii) Three drugs combination tablets containing Stavudine, Lamivudine and Nevirapine; iv) Three drug combination tablets containing Zidovudine, Lamivudine and Nevirapine; v) Efavirenz [3] . The following drugs are used for pediatric HIV management for children weighing up to 20 kg: FDCs i) Stavudine and Lamivudine; ii) Stavudine and Lamivudine; iii) Stavudine, Lamivudine and Nevarapine; iv) Stavudine, Lamivudine and Nevarapine; and v) Efavirenz [4] . But some drugs are still not available in India as single drugs, as per our analysis ( Table 3) . These include four protease inhibitors (Agenerase, Aptivus, Lexiva, and Prezista), one NNRTI (Rescriptor) and one Fusion inhibitor (Fuzeon) [7, 14] .
Thus, only about 150,000 people with HIV/AIDS access the ARVs from the public sector while some also get these through private health facilities, which dominate India's healthcare sector. But the vast majority of 2.4 million PLHA cannot afford to buy treatment privately. While the coverage of treatment continues to remain unacceptably low, improvements are being made to expand access to ARVs in a number of areas [15] . This is a massive challenge for the NACO, Govt. of India.
The HIV/AIDS is a chronic disease requiring lifelong treatment with different ARV combinations compounding the problem for people who also develop drug resistance and side effects over time [16] . Thus, increasing access to ARVs also means that an increasing number of people living with HIV in India are likely to develop resistance to the first line treatment necessitating switching over to the second line ARVs. Data from Africa show that over a five year period 22% people needed such a switch-over [16] . In addition, another study from South Africa found that within 3 years on ART, 21% of patients who had started a d4T-based regimen needed to be switched because of toxicity [17] . This resulted in a 2006 recommendation by the WHO to move away from d4T to less toxic combinations based on either AZT or tenofovir [18] , of course with a significant price implications. In 2008, the NACO began to roll out government funded second-line anti-retroviral treatment in two centres in Mumbai and Chennai [6] . There are also plans to improve the provision of nevirapine to pregnant mothers with HIV, which can significantly reduce the risk that they will pass infection on to their child [6] . In common with other parts of the developing world, the second line ARV treatment in India is currently prohibitively more expensive than the first line treatment which is essentially based on the generics.
Despite several global initiatives to provide ARV treatment in poor and middle income countries, like the 3 by 5 and the current efforts towards Universal Access, the outreach is still poor with the targets well behind with coverage of an estimated 3 million or about 31% of the 9.7 million needing the ARVs [15, 16] . What is more, about 2.5 million new infections were added during 2007 underscoring the massive task ahead. Another matter of serious concern is the estimated 2.1 million children under 15 years needing treatment while the coverage is about 10% only [15] . Funding for the purchase of the drugs remains a serious constraint with the gap between required and available resources of US$8.1 billion during 2007. To meet the universal targets, funding needs to be enhanced to at least four times to US$ 35 billion in 2010 and to US$41 billion in 2015 [15] . One critical factor continues to be the cost of ARVs [15] .
IMPACT OF NEW PATENT REGIMES
In the light of the new TRIPS-complaint IP regime [19] in India and other developing countries and the need to find innovative strategies to provide ARVs, there is a need to have a serious look at whether the strong IP protection system is a barrier. We therefore looked at the patent profile of ARV drugs both in India and the USPTO filed by the originator companies. Table 4 shows data on the patent profile of FDA approved ARVs. We could track 93 patents on ARVs filed in the USPTO by the originator companies. The major patent filers were Abbot, Gilead, Abbott, GSK etc. with the number of patents filed varying with the drug. (Table 5) .
Significantly, most generic antiretroviral agents currently now being used in Africa and Asia are manufactured in India as the Indian Patent Act (1970) permitted making generic copies of drugs in India [20] . With the largest global standard facilities for manufacturing outside the USA, the Indian companies were able to offer HIV drugs at a fraction of the cost of brand-name drugs. The new Indian patent Act (2005) has already created significant barriers for the development of new generics on ARVs patented in India after 2005 [21] . Developing countries had to allow inventors to file patent applications from January 1, 1995, and the decision on whether or not to grant any patent could be taken at the end of the transition period. This has potentially serious impact on global initiatives of MSF, PEPFAR, Clinton Foundation etc which source drugs from the Indian companies for distribution in African countries [20] .
There are also apprehensions that the first-line antiretroviral drug regimens in wide use may soon be found wanting to meet the needs of HIV-infected patients [22] . There is also evidence to show that some people may be intolerant to some drugs as also reports of contraindications that need attention [18, 23] . More importantly, there could be treatment failure necessitating drugs outside the available ARV drug regimens. In addition, without strong second-line therapeutic regimens HIV patients could well stand to lose the benefits of antiretroviral therapy. Worse still, they may transmit the drug-resistant virus to others compounding the problem. "Sustaining" may well soon surpass with "scaling up" of antiretroviral therapy emerging as the major challenge [22] . Brazil is already facing this challenge, and African and Asian countries with far fewer resources will probably encounter even greater hurdles in gaining access to secondline therapies [22] .
The impact of Trade Related Aspects of Intellectual Property Rights (TRIPs)-complaint legislation [19, 21] on access to ARVs to HIV-infected persons in resource-limited countries therefore cannot be overemphasized. There is a need to find solutions and find them fast. A dual approach may be required i) ensure the continued availability of high quality generics by manufacturers from India and elsewhere; and ii) encourage strong efforts towards developing new generics from patented drugs and new formulations through newer global strategies. For example, the US FDA has approved, under PEPFAR, several generic antiretroviral preparations for purchase and use outside the United States [10] .
There have been a few attempts by the originator companies, under intense criticism on their pricing policies, to license the ARV drugs. Table 6 shows data on licensing of ARV drugs by the originator companies to non-US companies, mostly in South Africa, other African countries and India. GSK has licensed to maximum companies outside the US -4 companies in the African continent. The BMS has licensed its drugs stavudine and didanosine to over 49 countries including India. Some companies like Gilead have licensed manufacture of its drugs to a large number of generic companies in India through non-exclusive licensing [24] . 
OPTIONS TO PROMOTE ACCESS TO NEWER ARVs
A priority now is to, among others, find less toxic firstline ARV combinations and drug options when resistance is developed [23] . The primary issue continues to be strong TRIPS-complaint global patenting regimes which impact the key generics-producing countries such as India, Brazil, and Thailand. The MSF estimates that the ARV prices are unlikely to see the dramatic 99% drop seen for the currently used first-line ARVs -from >$10,000 per patient per year in 2000 to $87 today [16] . National Governments of developing countries will therefore have difficult choices before them like whether to treat more number of patients on more affordable ARV combinations, or fewer people on less toxic but more expensive combinations.
Simple switching over from the most commonly used d4T-based first-line ARV combination to a less toxic option involves about twice the cost [23] . And changing over to a TDF-based ARV regimen would mean a 4-11 fold price increase [23] . According to MSF's estimates, replacing d4T with a TDF-based regimen for all patients from 2008 to 2014 (Table 4) (based on today's prices) would mean a 4-11 fold price increase [16, 25] . Unless there are overall price reductions the overall increase of cost for ARVs. in some middle-income countries could be as high as 17-fold [16] .
Besides the availability of generics for the first-line ARVs in countries with manufacturing capacity like India, Brazil, and Thailand, multiple producers and the resultant competition has actually brought down prices dramatically [16] . Globally, India is considered the "pharmacy of the developing world," as charities like MSF source over 80% of its ARVs from India as also other ARV providers like the Clinton Foundation, PEPFAR etc. [16, 20] . This was possible only because the pre-TRIPS patent regimes allowed the development of single drugs and FDCs, an innovation that not just simplified HIV/AIDS treatment but helped significant scale-ups. In the recent years, there have been aggressive patenting by originator companies in countries like India, Brazil and Thailand [26] [27] [28] .
The global battle for affordable ARVs, thus is likely to get tougher in future. Developing countries with significant PLHA need to use all the means available including public health safeguards and flexibilities enshrined in the WTO TRIPS as reiterated in the Doha Declaration [29] that allows countries to overcome patent barriers by issuing compulsory licenses (CLs) to open the market to competition despite patent protection.
Other options open to sovereign countries include design or interpret national patent laws to limit the scope of patentability of new chemical entities with a public health priority and other strategies [30, 31] . Like, for example, the Indian Patents Act (2005) that allows pre-grant opposition [32] . In June 2008 such an opposition was successfully contested in India for the pediatric syrup formulation of NVP as the Indian patent office rejected the patent [26] [27] [28] .
PATENT POOLS
In what is considered a path-breaking development, the UNITAID decided in principle in July 2008 to establish a patent pool for ARVs [33] that may hold the key for access to affordable newer ARVs in the future. This concept was originally mooted by the MSF, along with Essential Inventions to the UNITAID board in June 2006 to overcome the difficulties to access newer ARVs. As Ellen t'Hoen of the UNITAIDS explains [34] : "A patent pool is a mechanism whereby patent owners put their patents in a 'pool' and allow others who need access to those patents to use them in exchange for a royalty payment. Patent pools have, in fact, been used to drive forward innovation in many different fields of technology, for example in the development of recording equipment, where you need multiple patents to be able to produce a certain product". Hoen considers that the patent pooling as a strategy will not only help the development of new fixed-dose combination drugs that combine multiple compounds into one pill, especially for the newer drugs and in developing fixed-dose combinations or paediatric formulations [34] .
The advantages of patent pool appear to be huge. Like, for example, the development of pediatric formulations or the much-needed FDCs for less toxic first and second-line treatments. Patent filed by originator companies on individual compounds typically hamper the development of FDCs, a barrier that a patent pool would help break. Generic versions of new drugs also could be developed quickly through the patent pool as the generic companies need not wait for the 20-year patent expiration. If the patent pool is accessed by multiple companies, the resultant competition [35] had recommended exploring the feasibility of patent pools for diseases of the poor [36] . By the end of 2009, the UNITAID pool is eventually expected to run as a separate entity [37] .
The need for affordable ARVs to vulnerable sections of society like children, pregnant women and people with HIV-TB in resource-poor countries cannot be overemphasized. The urgency is especially for the paediatric populations as, of the 22 ARVs approved by the US FDA for adults, as many as 8 are not approved for use in children while 9 do not have any pediatric formulations [38] .
CONTRIBUTORSHIP
Kanikaram Satyanarayana conceived, designed and wrote the article.
Sadhana Srivastava shared in the draft preparation and participated in overall interpretation, revision and finalization of the paper.
